Provided by Tiger Trade Technology Pte. Ltd.

ZAI LAB

14.040
+0.4903.62%
Volume:7.20M
Turnover:101.66M
Market Cap:15.84B
PE:-6.91
High:14.390
Open:14.050
Low:13.900
Close:13.550
52wk High:35.500
52wk Low:12.310
Shares:1.13B
HK Float Shares:1.13B
Volume Ratio:0.95
T/O Rate:0.64%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-2.030
ROE:-28.97%
ROA:-13.29%
PB:2.67
PE(LYR):-6.91
PS:4.59

Loading ...

Zai Lab Limited (Stock Code: 09688) Announces January 2026 Monthly Return

Bulletin Express
·
Feb 05

JPMorgan Chase Increases Stake in Zai Lab by Approximately 1.92 Million Shares at HK$13.34 Per Share

Stock News
·
Feb 04

Haitong International Maintains "Outperform" Rating on Zai Lab (09688), Sees Dual Engines Driving Long-Term Global Value

Stock News
·
Jan 30

JPMorgan Chase & Co's Long Position in Zai Lab Ltd Reduced to 4.46% on Jan 12 From 5.11% - HKEX Filing

THOMSON REUTERS
·
Jan 16

Zhutong Hong Kong Stock Morning Briefing | Ministry of Finance Holds Meeting on Fiscal-Financial Synergy to Boost Domestic Demand; White House Announces 25% Tariff Hike on Specific Semiconductors

Stock News
·
Jan 15

Stock Track | Zai Lab Soars 7.3% Intraday on Clinical Progress Revealed at JPMorgan Healthcare Conference

Stock Track
·
Jan 14

Zai Lab Rises Over 7% in Morning Session Following Appearance at JPMorgan Healthcare Conference

Deep News
·
Jan 14

Asian Equities Traded in the US as American Depositary Receipts Slightly Higher in Tuesday Trading

MT Newswires Live
·
Jan 13

Zai Lab Announces 2026 Strategic Plan Focused on Advancing Global Pipeline, Launching New Products, and Expanding Clinical Development Programs

Reuters
·
Jan 13

Zai Lab Highlights Strategic Priorities and Global Pipeline Progress at 44TH Annual J.p. Morgan Healthcare Conference

THOMSON REUTERS
·
Jan 13

Asian Equities Traded in the US as American Depositary Receipts Rise Sharply in Monday Trading

MT Newswires Live
·
Jan 12

Novocure Reports Record 2025 Revenue with 8% Annual Growth

Reuters
·
Jan 12

BRIEF-Zai Lab Announces National Medical Products Administration (Nmpa) Approval Of Augtyro™

Reuters
·
Jan 06

China Approves Zai Lab's AUGTYRO for NTRK-Positive Solid Tumors

Reuters
·
Jan 06

Zai Lab Announces National Medical Products Administration (Nmpa) Approval of Augtyro™ (Repotrectinib) for Patients With Ntrk-Positive Solid Tumors

THOMSON REUTERS
·
Jan 06

Zai Lab to Present at J.P. Morgan Healthcare Conference

Reuters
·
Jan 05

Zai Lab Officer Rafael Amado Reports Sale of Common Shares

Reuters
·
Jan 03

Asian Equities Traded in the US as American Depositary Receipts Climb in Friday Trading

MT Newswires Live
·
Jan 02

Stock Track | Zai Lab Soars 5.06% as Breakthrough Schizophrenia Drug KAI JIE LE Gains Approval in China

Stock Track
·
Dec 24, 2025

HK Stock Movement | Zai Lab (09688) Rises Over 4% in Early Trading as Breakthrough Schizophrenia Drug KAI JIE LE Gains Approval in China

Stock News
·
Dec 24, 2025